Details
| Stereochemistry | MIXED |
| Molecular Formula | C15H12N2O2 |
| Molecular Weight | 252.268 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)N1C2=CC=CC=C2C3OC3C4=CC=CC=C14
InChI
InChIKey=ZRWWEEVEIOGMMT-UHFFFAOYSA-N
InChI=1S/C15H12N2O2/c16-15(18)17-11-7-3-1-5-9(11)13-14(19-13)10-6-2-4-8-12(10)17/h1-8,13-14H,(H2,16,18)
| Molecular Formula | C15H12N2O2 |
| Molecular Weight | 252.268 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. | 2009-06 |
|
| Approaches to treatment of type 2 diabetes. | 2008-08 |
|
| Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. | 2006-11 |
|
| Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations. | 2005-07 |
|
| Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. | 2005-06 |
|
| Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. | 2005-03 |
|
| In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. | 2003-06 |
|
| Elevation of carbamazepine-10,11-epoxide by quetiapine. | 2002-11 |
|
| Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation. | 2002-09-05 |
|
| Administration of Carbatrol to children with feeding tubes. | 2002-09 |
|
| The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation. | 2001-02 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:56:20 GMT 2025
by
admin
on
Mon Mar 31 21:56:20 GMT 2025
|
| Record UNII |
QC9505F279
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
36507-30-9
Created by
admin on Mon Mar 31 21:56:20 GMT 2025 , Edited by admin on Mon Mar 31 21:56:20 GMT 2025
|
PRIMARY | |||
|
DTXSID60891456
Created by
admin on Mon Mar 31 21:56:20 GMT 2025 , Edited by admin on Mon Mar 31 21:56:20 GMT 2025
|
PRIMARY | |||
|
3388
Created by
admin on Mon Mar 31 21:56:20 GMT 2025 , Edited by admin on Mon Mar 31 21:56:20 GMT 2025
|
PRIMARY | |||
|
QC9505F279
Created by
admin on Mon Mar 31 21:56:20 GMT 2025 , Edited by admin on Mon Mar 31 21:56:20 GMT 2025
|
PRIMARY | |||
|
2555
Created by
admin on Mon Mar 31 21:56:20 GMT 2025 , Edited by admin on Mon Mar 31 21:56:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BINDER->LIGAND |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
